Study of Breast Cancer Prevention by Letrozole in High Risk Women
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 30 - 69 |
| Updated: | 2/28/2019 |
| Start Date: | October 2006 |
| End Date: | March 2015 |
This is a multi-institution double-blind placebo-controlled trial whose main objective is to
determine if 6 months of letrozole (2.5 mg daily) can reduce proliferation as assessed by
Ki-67 in high risk postmenopausal women on systemic hormone replacement therapy who have
random periareolar fine needle aspiration (RPFNA) evidence of hyperplasia with atypia or
borderline atypia, and a minimum Ki-67 of >1.5%.
The primary hypothesis is that proliferation and expression of other estrogen response genes
will be favorably modulated by six months of letrozole relative to placebo without
substantially increasing hot flashes or worsening overall quality of life.
determine if 6 months of letrozole (2.5 mg daily) can reduce proliferation as assessed by
Ki-67 in high risk postmenopausal women on systemic hormone replacement therapy who have
random periareolar fine needle aspiration (RPFNA) evidence of hyperplasia with atypia or
borderline atypia, and a minimum Ki-67 of >1.5%.
The primary hypothesis is that proliferation and expression of other estrogen response genes
will be favorably modulated by six months of letrozole relative to placebo without
substantially increasing hot flashes or worsening overall quality of life.
Subsequent to the 6 month RPFNA for assessment of biomarkers, toxicity and quality of life
assessments, all women may receive optional open-label letrozole for an additional 6 months,
followed by a third RPFNA and biomarker
assessments, all women may receive optional open-label letrozole for an additional 6 months,
followed by a third RPFNA and biomarker
Inclusion Criteria:
- Post-menopausal women at high risk for development of breast cancer
- On a stable dose of hormone replacement therapy
- have cytomorphologic evidence of hyperplasia +/- atypia and Ki-67 expression >1.5% in
benign breast epithelial cells acquired by RPFNA
- Serum level of 25-OH vitamin D of at least 30 ng/ml prior to study entry
- Willing to have a repeat random periareolar fine needle aspiration (RPFNA) and
mammogram at 6 months and 12 months (if participating in the open label portion of the
study) following initiation of study drug
Exclusion Criteria:
- Prior history of osteoporosis or osteoporotic fracture.
- Prior history of invasive breast cancer or other invasive cancer within five years
from date of study entry.
- Current and chronic use of cyclooxygenase-2 (COX-2) specific inhibitors or NSAIDs
- Receiving treatment for rheumatoid arthritis or fibromyalgia
- Current history of poorly controlled migraines or perimenopausal symptoms
- Currently receiving other investigational agents.
- Receipt of more than 6 months of an aromatase inhibitor (anastrozole, exemestane,
letrozole, etc.) at any time in the past.
We found this trial at
1
site
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
Click here to add this to my saved trials
